1.Research advances in gold nanoparticle radiosensitization in radiotherapy for cancer
Fangfang NIE ; Chunfu ZHANG ; Jie FU
Chinese Journal of Radiation Oncology 2016;25(8):907-910
Gold nanoparticles ( AuNPs) have been widely used in biomedicine due to their unique physical and chemical properties as well as good biocompatibility. Current research in this field has been focused on AuNP radiosensitization in radiotherapy for cancer. Extensive studies in vivo and in vitro have showed the radiosensitization effect of AuNPs. However, the mechanism of radiosensitization by AuNPs still requires further studies. Right now, the radiation?insensitive phase ( G0+G1 phase) to radiation?sensitive phase ( G2+M phase ) transition of tumor cells by AuNPs is widely considered as the main cause of radiosensitization. There are many influencing factors for AuNP radiosensitization such as particle size, surface modification, microscopic distribution, radiation energy, radiation dose, and type of tumor cells. Moreover, safety should also be taken into account in AuNP radiosensitization. Clinical trials of AuNPs have been carried out right now. More studies on AuNP radiosensitization are needed to achieve real clinical transformation.
2.Effects of different conserve time on physiological characteristics of allograft nerve transplantation
Yong ZHANG ; Delong CHEN ; Xiaolong CHEN ; Xiyin ZENG ; Chunfu NIE
Chongqing Medicine 2013;(29):3521-3523,3526
Objective To observe the effect of different conserve time in ultra deep cryopreservation (-196 ℃)on physiological characteristics of allograft nerve transplantation .Methods A total of 80 female Wistar rats were divide into three groups by random principle:derived group which 20 rats were sacrificed to get both sides of femoral nerves ;control groups which each group had 10 rats include group A for fresh autologous nerve transplantation ,group B for fresh allograft nerve transplantation ;experiment groups which each group had 10 rats including groups C ,D ,E ,F that transplanted after femoral nerves conserve in the -196 ℃ for 3 ,6 ,9 , 12 weeks respectively ,and the results of exterior appearance ,light microscope ,electron microscope were observed and electrophysi-ological test was conducted after transplantation .Results After 9 weeks transplantation :the physiological characteristics of group B was most affected ,followed by group C ,D ,E ,F ,group A was with minimal impact ;the result of electrophysiological test showed that groups A&B ,A&E ,A&F had significant difference(P<0 .05) .Conclusion The physiological characteristics of allograft nerve transplantation relate to the freezing time .
3.The effects of conditioned medium from keloid fibroblasts under hypoxia on angiogenesis.
Zhe ZHANG ; Chunfu KANG ; Bin CHEN ; Fangfei NIE ; Jianxun MA ; Zelian QIN
Chinese Journal of Plastic Surgery 2014;30(4):283-288
OBJECTIVETo observe the effects of conditioned medium from keloid fibroblasts under hypoxia on angiogenesis, and to investigate the role of hypoxic microenvironment in invasive growth of keloid.
METHODSPrimary keloid fibroblasts and human umbilical endothelial cells (HUVEC) were cultured as conventional method. Keloid fibroblasts were cultured either in a hypoxic incubator (2% O2) for 48 h or in a normoxic incubator (20% O2) as control. Then those cell culture mediums were collected and mixed with endothelial cell medium by the proportion of 1:1 as conditioned medium. The mRNA and secreted protein of pro-angiogenic factors such as vascular endothelial growth factor (VEGF), angiopoietin-1 (Ang-1) and periostin of keloid fibroblasts under hypoxia were detected by real time PCR and ELISA. The proliferation, migration and invasion, tube formation of HUVEC cultured with conditioned medium were evaluated by CCK-8 assay, Transwell assay and matrigel tube formation assay, respectively.
RESULTSHypoxia increased the expression of VEGF, Ang-1 and periostin in both mRNA (increased by 75%, 43% and 118% respectively, P < 0.05) and secreted protein (increased by 30.2%, 14.2% and 19.5% respectively, P < 0.05) levels; the proliferations of HUVEC in hypoxic conditioned medium in 1, 2 and 3 d were 0.67 +/- 0.07, 0.84 +/- 0.09 and 1.08 +/- 0.10 respectively, which were higher compared to those in control group (0.52 +/- 0.08, 0.72 +/- 0.10 and 0.91 + 0.14, P < 0.05); the numbers of migration, invasion and tube formation of HUVEC were (73.2 +/- 8.9), (56.3 +/- 12.5), (9.66 +/- 1.96) cells/HP, which were higher compared to those in control group [(59.0 +/- 8.0), 35.5 +/- 8.5), (6.5 +/- 1.87) cells/HP, P < 0.05].
CONCLUSIONSHypoxia increases the expression of pro-angiogenic factors of keloid fibroblasts, and its conditioned medium under hypoxia could promote angiogenesis. The results suggest hypoxic microenvironment may play a significant role in the invasive growth of keloid by inducing angiogenesis.
Cell Hypoxia ; Cells, Cultured ; Culture Media, Conditioned ; Fibroblasts ; Humans ; Keloid ; pathology ; Neovascularization, Pathologic
4.Field evaluation of BinaxNOW~ rapid diagnostic devices for malaria
Hui LIU ; Ruihai JIA ; Chunfu LI ; Renhua NIE ; Yuanhong SUN ; Guishen LI ; Xu SHEN
Chinese Journal of Schistosomiasis Control 1992;0(06):-
Objective To evaluate the effect of BinaxNOW rapid diagnostic devices for malaria in the field. Methods The symptomatic patients were detected by using the BinaxNOW devices and the results were compared with the microscopic examination of Giemsa-stained blood smears(as a golden standard). The sensitivity and specificity were calculated. The double-blind method was used in this study. Results In 443 symptomatic patients,151 cases were positive for malaria. The sensitivity was 98.69% and the specificity was 100%,and the coincidence rate of BinaxNOW with the microscopic examination was 99.55%. The sensitivity and specificity of Plasmodium falciparum were 100% and 99.66%,respectively,and the coincidence rate was 99.76%. The sensitivity and specificity of non-falciparum Plasmodium were 90.91% and 100%,respectively,and the coincidence rate was 99.36%. Conclusion The BinaxNOW rapid diagnostic devices for malaria are sensitive,specific,and stable for malaria diagnosis in the field.
5.Clinical analysis of the second-line treatment with lenvatinib plus camrelizumab in 12 cases of advanced intrahepatic cholangiocarcinoma
Jiankang ZHANG ; Yi LIU ; Dong DING ; Zhihuai WANG ; Yuhang SHEN ; Qingyu SUN ; Bin NIE ; Chunfu ZHU ; Xihu QIN ; Yuan GAO
Chinese Journal of Hepatobiliary Surgery 2024;30(3):171-174
Objective:To evaluate the efficacy and safety of lenvatinib combined with camrelizumab as the second-line treatment for advanced intrahepatic cholangiocarcinoma (ICC).Methods:The clinical data of patients with advanced ICC undergoing the second-line treatment of lenvatinib combined with camrelizumab in the Affiliated Changzhou No. 2 People's Hospital of Nanjing Medical University from June 2021 to June 2022 were screened and analyzed. A total of 12 patients were enrolled, including seven males and five females, aged (67.5±8.6) years. Response evaluation criteria in solid tumor 1.1 was used to evaluate the efficacy of treatment. The safety assessment adopts the Adverse Event Evaluation Standard 5.0. Kaplan-Meier method was conducted to plot survival curves.Results:Among the 12 patients (after 1-7 cycles of immune and targeted therapy), three achieved partial response, four achieved stable disease, and five were defined as progression disease. Adverse events of different degrees occurred in seven cases, among which three patients had adverse events of grade ≥ 3: one with hypertension, which was managed after antihypertensive and symptomatic treatment; one with elevated serum total bilirubin, which was improved after reducing the dose of lenvatinib; one with liver dysfunction, which was considered as immune-related liver toxicity and alleviated after discontinuing camrelizumab. The 1-month, 3-month, and 6-month survival rates and progression-free survival rates of the patients were 100.0%, 91.7%, 66.7%, and 83.3%, 41.7%, and 25.0%, respectively. The median overall survival of patients was 14.7 months (95% CI: 9.2-21.2) and the median time to progression was 8.0 months (95% CI: 4.1-11.9). Conclusion:Combination of lenvatinib and camrelizumab could bring survival benefits with controllable adverse events as the second-line treatment of patients with advanced ICC.